Thyroid Eye Disease: Multidisciplinary Management of Treatment-Associated Hearing Loss (CE Monograph)

Activity Description and Purpose

This educational activity is intended to help clinicians evaluate real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment with the insulin-like growth factor 1 receptor antagonist teprotumumab. Clinicians will learn how to implement optimal strategies for monitoring and managing hearing loss in patients treated with teprotumumab. The desired results of this activity are for clinicians to use a multidisciplinary approach to increase their ability to identify and manage hearing loss in patients who require treatment of thyroid eye disease.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Evaluate key and impactful real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment
  • Implement optimal strategies for monitoring and managing hearing loss in patients treated with insulin-like growth factor-1 receptor antagonists for thyroid eye disease
Course summary
Available credit: 
  • 1.50 COPE
Course opens: 
Course expires: 


Prem S. Subramanian, MD, PhD (Chair)
Chief, Neuro-Ophthalmology
Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology
Vice Chair for Academic Affairs, Ophthalmology
Professor in Ophthalmology, Neurology, and Neurosurgery
Sue Anschutz-Rodgers University of Colorado Eye Center
University of Colorado School of Medicine
Aurora, Colorado

Jennifer Alyono, MD, MS
Clinical Assistant Professor, Otolaryngology (Head and Neck Surgery)
Stanford Medicine
Stanford, California

César A. Briceño, MD
Associate Professor of Clinical Ophthalmology
Associate Professor of Ophthalmology in Dermatology
Scheie Eye Institute
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.


Jennifer Alyono, MD, MS, is a contracted researcher for Astellas Pharma US, Inc,* and Cochlear Ltd.

César A. Briceño, MD, is an advisory board member of Amgen Inc, F. Hoffmann-La Roche Ltd, and Genentech, Inc.

Prem S. Subramanian, MD, PhD, is a consultant for Acelyrin, Inc; is an advisory board member of Amgen Inc, GenSight Biologics, Kriya Therapeutics, and Viridian Therapeutics, Inc; and is a contracted researcher for Immunovant, Inc, Invex Therapeutics*, Neurophth Therapeutics, and Tourmaline Bio, Inc.

Peer Reviewer

Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 89849-SD (Asynchronous)
COPE Course Category: Treatment & Management of Ocular Disease


This activity, COPE Activity Number 127828, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Amgen Inc for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Amgen Inc.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 308b

Available Credit

  • 1.50 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.